VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Treating migraines in patients not responding to CGRP monoclonal antibodies

Simona Sacco, MD, University of L’Aquila, L’Aquila, Italy, explains that despite the introduction of new, efficacious anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, there are unmet needs in patients that do not respond to these agents. In fact, reports suggest 30-50% of patients are non-responders, indicated by individuals’ number of monthly headache days. These patients require new treatment options. Additionally, the ESTEEMen prospective study showed that among patients considered as responders, a quarter still had more than eight headache days per month, which is a substantial residual headache burden. Prof. Sacco believes researchers should focus on both groups of patients to improve their quality of life. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.

Disclosures

Lilly, Teva, Novartis, Allergan-Abbvie-Pfizer, AstraZeneca, NovoNordisk, Lundbeck